Table 3. Indicators of quality of life and psychiatric disorders in patients with CMT, non-exclusive categories.
*According Table 1.
| Variable (n=number of studies) | Instruments (No. of study)* |
|---|---|
| Quality of life impairment n=10 | CMT>Cs, n=8(5,7,8,12,13,14,18,19) |
| CMT<rLTNCs(19) | |
| Positive correlation with muscle strength impairment, n=4 (8,11,12,13) | |
| Positive correlation with deambulation deficit, n=3(6,8,11) | |
| Positive correlation with fatigue, n=1(18) | |
| Psychiatric disorders n=13 | |
| Depressive disorders n=8 | CMT=Cs, n=2(4,17) |
| CMT > Cs, n=1(16) | |
| CMT < MD, n=2(1,16) | |
| CMT=MD, n=1(9) | |
| CMT=FSHD, n=1(9) | |
| CMT=stroke, n=1(4) | |
| Positive correlation with reduced quality of life and depressive symptoms, n=4(6,8,9,11) | |
| Absence of correlation between depressive symptoms and physical impairments, n=2(4,16) | |
| Absence of correlation between depressive symptoms and disease progression, n=1(8) | |
| Anxiety disorders n=3 | CMT=MD and FSHD, n=1(9) |
| CMT < MD, n=1(16) | |
| CMT < Cs, n=1(16) | |
| CMT=Cs, n=1(17) | |
| Sleep disorders n=9 | CMT > Cs, n=6(2,3,4,15,16,18,20) |
| CMT=Cs, n=1(10) | |
| CMT > stroke, FSHD, NIN, n=2(4,9,15) | |
| CMT > MD, n=1 (9) | |
| CMT < MD, n=1(1) | |
| CMT=MD, n=1(16) |
Cs, healthy controls; MD, myotonic dystrophy; FSHD, facioscapulohumeral dystrophy; NIN, non-inherited neuropathy (acquired); rLTNCs, rare long-term neurologic conditions (Huntington's disease, cerebellar ataxia, motor neurone disease, multiple system atrophy, progressive supranuclear plasy, postpolio syndrome); CMT, Charcot–Marie–Tooth disease.